About 3D MEDICINES Company

3D Medicines Inc. (www.3d-medicins.com) is a pharmaceutical company that has entered the commercialization stage focusing on the field of cancer treatment. Adhering to the vision of “helping cancer patients live longer and better”, it is developing next-generation oncology drugs for cancer patients around the world in line with the future trend of chronic cancer treatment. The company's product line includes 12 innovative drug candidates with clinical value, differentiated or world-leading, of which 8 have entered the clinical development or commercialization stage, including Envida, the world's first subcutaneous PD-L1 single-domain antibody drug, has been conditionally approved by the State Drug Administration for marketing in China; the introduction of first-in-class polypeptide tumor vaccine 3D189 and the GAS6/axl inhibitor 3D229 has been approved by the FDA to carry out global phase III MRCT clinical research; the self-developed multi-target kinase inhibitor 3D011 has also entered clinical trials. During the development phase, four other products targeting FGFR123\ EP4\ COX2\ CD47 respectively also entered the clinical stage at home and abroad. Pre-clinical varieties also include the internationally leading dual antibody CD3xPD-L1. The company currently has an international team of more than 250 people to develop, produce and commercialize new drugs to explore better treatments for cancer patients around the world.